Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.

Abstract

OBJECTIVES:

Early osteoporotic fractures have a great impact on disease progression, the first fracture being a major risk factor for further fractures. Strontium ranelate efficacy against vertebral fractures is presently assessed in a subset of women aged 50-65 years.

METHODS:

The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international, double blind, placebo controlled trial, supporting the efficacy of strontium ranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. 353 of these randomly assigned women were included in this analysis.

RESULTS:

Over 4 years, strontium ranelate significantly reduced the risk of vertebral fracture by 35% (relative risk 0.65; 95% CI 0.42 to 0.99, p<0.05). In the strontium ranelate group, the bone mineral density increased from baseline by 15.8% at lumbar spine and 7.1% at femoral neck.

CONCLUSION:

These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women aged 50-65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient.

• Authors: C Roux, J Fechtenbaum, S Kolta, G Isaia, J B Cannata Andia, J-P Devogelaer
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 67 Issue 12 Pg. 1736-8 (Dec 2008) ISSN: 1468-2060 [Electronic] England
• PMID: 18713788 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Bone Density Conservation Agents
• Organometallic Compounds
• Thiophenes
• strontium ranelate

Topics

• Aged
• Body Mass Index
• Bone Density (drug effects)
• Bone Density Conservation Agents (therapeutic use)
• Double-Blind Method
• Female
• Femur Neck (physiopathology)
• Humans
• Lumbar Vertebrae (physiopathology)
• Middle Aged
• Organometallic Compounds (therapeutic use)
• Osteoporosis, Postmenopausal (complications, drug therapy, physiopathology)
• Radiography
• Spinal Fractures (diagnostic imaging, etiology, physiopathology, prevention & control)
• Thiophenes (therapeutic use)
• Treatment Outcome